| Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma (NCT04961320) | City of Hope Medical Center | 2022-07-15 |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (NCT04981509) | National Cancer Institute (NCI) | 2022-06-10 |
| Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer (NCT04904302) | M.D. Anderson Cancer Center | 2022-05-03 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373) | M.D. Anderson Cancer Center | 2022-04-29 |
| Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer (NCT05012371) | M.D. Anderson Cancer Center | 2022-02-16 |
| Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy (NCT05112627) | Mayo Clinic | 2022-01-24 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (NCT05122546) | City of Hope Medical Center | 2021-11-01 |
| Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer (NCT04603365) | Jonsson Comprehensive Cancer Center | 2021-10-18 |
| App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell Cancer (NCT04788095) | City of Hope Medical Center | 2021-08-23 |
| Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery (NCT04588246) | NRG Oncology | 2021-08-05 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (NCT04902040) | M.D. Anderson Cancer Center | 2021-04-14 |
| Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial (NCT04693377) | M.D. Anderson Cancer Center | 2021-03-16 |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial (NCT04510597) | SWOG Cancer Research Network | 2021-03-08 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases (NCT04752267) | University of Southern California | 2021-02-15 |
| Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery (NCT04370509) | University of California, San Francisco | 2021-02-09 |
| Cancer and Blood Pressure Management, CARISMA Study (NCT04467021) | ECOG-ACRIN Cancer Research Group | 2020-10-29 |
| DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers (NCT04388852) | M.D. Anderson Cancer Center | 2020-08-20 |
| Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (NCT04071223) | National Cancer Institute (NCI) | 2020-07-29 |
| Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma (NCT04393350) | Emory University | 2020-06-22 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes (NCT04501913) | City of Hope Medical Center | 2019-12-24 |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (NCT03793166) | National Cancer Institute (NCI) | 2019-06-07 |
| CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (NCT03829111) | City of Hope Medical Center | 2019-05-14 |
| Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 (NCT03284385) | National Cancer Institute (NCI) | 2019-01-29 |
| A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) (NCT03595124) | National Cancer Institute (NCI) | 2019-01-08 |
| Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer (NCT03587662) | M.D. Anderson Cancer Center | 2018-08-17 |
| Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma (NCT03575611) | M.D. Anderson Cancer Center | 2018-06-14 |
| Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer (NCT03473730) | M.D. Anderson Cancer Center | 2018-05-29 |
| Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma (NCT03541902) | M.D. Anderson Cancer Center | 2018-05-15 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (NCT02496208) | National Cancer Institute (NCI) | 2015-07-22 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (NCT02298959) | National Cancer Institute (NCI) | 2015-04-08 |